Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Beigene Ltd (BGNE)  
$313.36 2.69 (0.85%) as of 4:30 Mon 12/22


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 90,630,000
Market Cap: 28.40(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $175.1 - $377.47
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 134,958 323,845 1,738,136 20,856,979
Total Sell Value $43,220,523 $100,045,046 $457,892,245 $2,147,483,647
Total People Sold 4 8 9 11
Total Sell Transactions 10 28 61 94
End Date 2025-09-21 2025-06-20 2024-12-20 2023-12-21

   
Records found: 692
  Page 1 of 28  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Oyler John Chief Executive Officer   •       •      –    2025-12-16 4 AS $300.80 $7,380,739 D/D (24,369) 0 4%     
   Oyler John Chief Executive Officer   •       •      –    2025-12-15 4 AS $301.58 $23,278,679 D/D (75,631) 24,369 2%     
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-12-11 4 AS $325.00 $107,900 D/D (332) 0 -1%     
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-12-11 4 OE $159.03 $63,598 D/D 332 332     -
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-12-10 4 AS $318.28 $105,669 D/D (332) 0 -2%     
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-12-10 4 OE $159.03 $63,598 D/D 332 332     -
   Sanders Corazon (corsee) D. Director   –       •      –    2025-11-26 4 S $340.20 $895,534 D/D (2,627) 0 7%     
   Sanders Corazon (corsee) D. Director   –       •      –    2025-11-26 4 OE $159.03 $417,772 D/D 2,627 2,627     -
   Wu Xiaobin President and COO   •       –      –    2025-11-17 4 S $380.23 $1,518,303 D/D (3,991) 0 16%     
   Wu Xiaobin President and COO   •       –      –    2025-11-13 4 S $380.33 $2,286,660 D/D (6,009) 0 14%     
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-11-12 4 AS $348.75 $347,770 D/D (996) 0 -16%     
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-11-12 4 OE $159.03 $190,704 D/D 996 996     -
   Wu Xiaobin President and COO   •       –      –    2025-11-12 4 S $350.44 $3,560,161 D/D (10,000) 6,009 16%     
   Oyler John Chief Executive Officer   •       •      –    2025-11-12 4 GD $0.00 $0 D/D 858,533 6,441,041     -
   Oyler John Chief Executive Officer   •       •      –    2025-11-11 4 GD $0.00 $0 D/D 151,320 7,299,574     -
   Wang Xiaodong Chair, Scientific Advisory Brd   –       •      –    2025-11-07 4 GD $0.00 $0 D/D 424,073 4,582,601     -
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-10-08 4 AS $347.82 $3,739,108 D/D (10,671) 0 -10%     
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-10-08 4 OE $159.03 $2,017,363 D/D 9,559 9,559     -
   Oyler John Chief Executive Officer   •       •      –    2025-09-16 4 AS $324.12 $9,055,694 D/D (27,803) 0 -3%     
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-09-10 4 AS $325.00 $3,257,289 D/D (10,006) 0 1%     
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-09-10 4 OE $159.03 $1,752,981 D/D 8,894 8,894     -
   Wang Lai Global Head of R&D   •       –      –    2025-09-09 4 AS $350.06 $1,750,312 I/I (5,000) 0 -10%     
   Wang Xiaodong Chair, Scientific Advisory Brd   –       •      –    2025-09-09 4 GD $0.00 $0 D/D 148,096 5,006,674     -
   Sanders Corazon (corsee) D. Director   –       •      –    2025-09-05 4 S $337.00 $898,105 D/D (2,665) 0 8%     
   Sanders Corazon (corsee) D. Director   –       •      –    2025-09-05 4 OE $155.68 $414,887 D/D 2,665 2,665     -
  692 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 28
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us